Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 341-360 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 341 | NeevCloud lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supportable because no direct positive evidence survived the 90-day recent evidence window in the retained reviewed sources. Why now: Why now is weak: despite membership rationale referring to partnerships and orbital data center / AI inferencing context, the retained reviewed sources contain zero evidence after recent evidence window and no citable article summaries. Caveats: Phase-2 membership rationale references, and: but no summaries or direct evidence are retained here for factual claims. The reviewed sources itself says NeevCloud is space-adjacent and not clearly a qualifying space company. |
| 342 | Neo Space Group lowweak | Opp 1 Risk 2 | Thesis: Potential opportunity exists if Neo Space Group is a meaningful customer or distribution node for satellite imagery supply to the Saudi government, but the reviewed sources does not provide available direct evidence within the recent evidence window to assess durability or monetization. Why now: No validated near-term or durable timing signal is available in the available evidence. Recency is uncertain because zero after-recent evidence window evidence were available. Caveats: Phase-2 rationale references, but no or summary is provided in the reviewed sources. Counterparty context should not be treated as propagated evidence for Neo Space Group's own thesis. Coverage debug shows zero evidence after recent evidence window. |
| 343 | NewOrbit lowweak | Opp 1 Risk 1 | Thesis: Reviewed evidence rationale says NewOrbit raised a £13.8 million Series A and is building VLEO sovereign communications satellites, but no retained evidence are present here to support a stronger ranked opportunity. Why now: No retained post-recent evidence window evidence are available, so current timing cannot be established from these reviewed sources. Caveats: Only membership rationale supports the company in this screen. No citeable retained evidence after recent evidence window. |
| 344 | OHB SE lowweak | Opp 1 Risk 1 | Thesis: No within the recent evidence window direct positive evidence was available, so there is insufficient reviewed sources support to form a positive 1 year+ opportunity thesis. Why now: There is no retained article or evidence row after the 90-day recent evidence window for OHB SE; recency-based ranking is therefore not supported by the reviewed sources. Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Phase-2 cohort membership rationale is not directional evidence and cannot substitute for retained article evidence. Because no article were retained after recent evidence window, no company-specific factual thesis can be cited from these reviewed sources. |
| 345 | Optimized Electrotech Pvt Ltd lowweak | Opp 1 Risk 1 | Thesis: The membership rationale suggests funding and expansion into space-based sensing with initial satellite platform orders, but the reviewed sources provide no retained within the recent evidence window article evidence or to support a positive thesis. Why now: No retained company evidence after the 90-day recent evidence window means there is no evidence-set-backed timing reason to rank this name higher now. Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership rationale cites article IDs, and, but no or retained evidence text are available here. Without retained article evidence, absence of bad news is not positive evidence. |
| 346 | Orbex mediumweak | Opp 1 Risk 5 | Thesis: Orbex has only minimal current opportunity evidence in these reviewed sources because the cited article context about its Prime microlauncher predates the 90-day recent evidence window and therefore should not be relied on as current support. Why now: The only surfaced article is dated February 17, 2026, outside the reviewed sources cutoff date of March 29, 2026, and the evidence recent evidence review says both rows were dropped; the article summary said Orbex released new photographs of its microlauncher Prime 'as the company looks to secure a future'. Because this is outside recent evidence window, recency support is absent. Evidence
Caveats: Primary surfaced evidence is outside recent evidence window and should not be treated as current proof. No in-recent evidence window direct positive or negative evidence is available. |
| 347 | OrbitOn lowweak | Opp 1 Risk 1 | Thesis: OrbitOn appears in an external SpaceFund satellite-servicing listing as 'Developing an on-orbit satellite servicing solution,' which is relevant product context, but the article is dated March 4, 2025 and was dropped by the 90-day recent evidence window, so it cannot support a current scored opportunity thesis in these reviewed sources Why now: Why now is weak because the only visible article has March 4, 2025 on a source date basis and the reviewed sources report no current evidence was retained after the March 29, 2026 cutoff Evidence
Caveats: Only article detail shown is outside the 90-day recent evidence window and was dropped. Database/listing style evidence is weaker than company-specific event evidence. External supporting source context is relevance context, not stronger than direct retained evidence. |
| 348 | Palantir Technologies lowweak | Opp 1 Risk 2 | Thesis: This reviewed sources does not provide citable reviewed evidence to support an opportunity thesis for Palantir despite a membership rationale mentioning possible participation in a U.S. Space Force Golden Dome context. Why now: Why now is weak because the reviewed sources references article IDs, and in the membership rationale, but no or reviewed evidence are provided for ranking use. Caveats: High mention count is not conviction. Cohort relevance via Space Force context is not enough without direct event/fact evidence. Coverage debug shows zero evidence after recent evidence window despite large article universe. |
| 349 | Paras Defence and Space Technologies Ltd lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supported within the reviewed sources' 90-day evidence window. The only cited reviewed sources rationale is older context that the company incorporated a semiconductor subsidiary, but no within the recent evidence window direct positive evidence is available in these reviewed sources. Why now: There is no available within the recent evidence window evidence row after the March 29, 2026 cutoff; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for Paras Defence and Space Technologies Ltd. Caveats: Phase-2 membership rationale references article, but the reviewed sources does not provide or quoted evidence for that item, so it cannot be used as a factual directional citation. No direct positive or negative evidence survived the 90-day recent evidence window. |
| 350 | Parsons Corporation lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources only provides older membership context that Parsons has 'space' among technology areas and appears in an SSA market report, but no within the recent evidence window direct positive evidence is available, so no positive thesis is supportable here. Why now: There is no available within the recent evidence window evidence row after the March 29, 2026 cutoff; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for Parsons Corporation. Caveats: Phase-2 membership rationale references articles: and, but the reviewed sources provide no for citation. Article-level market-report inclusion is weaker than direct company-specific operating evidence. |
| 351 | PhysicsX lowweak | Opp 1 Risk 1 | Thesis: Phase-2 rationale says PhysicsX raised $300M, but the reviewed sources characterizes the source as a broad tech funding roundup and provides no retained direct positive evidence inside the 90-day window, so the opportunity case is not currently evidenced. Why now: There is no current catalyst evidence because articles after recent evidence window = 0 and evidence after recent evidence window = 0. Caveats: Funding-round context in rationale lacks -cited retained evidence here. Space relevance is explicitly weak in the reviewed sources rationale. |
| 352 | PierSight lowweak | Opp 1 Risk 1 | Thesis: Insufficient admissible reviewed sources evidence to support a positive thesis within the selected recent evidence window, despite membership rationale describing PierSight as building the Varuna 2.0 SAR and AIS maritime-monitoring satellite. Why now: Why now is unsupported because the reviewed sources show no surviving evidence after recent evidence filtering; there is no direct dated milestone or problem signal to anchor a 1 year+ thesis. Caveats: Only membership-level rationale is present; no citable evidence survived. No direct company-specific positive or negative events are available in the reviewed sources. Low scores reflect evidence scarcity. |
| 353 | Pixxel lowweak | Opp 1 Risk 1 | Thesis: The earlier Pixxel reviewed sources version suggests Earth-observation and fundraising relevance in membership rationale, but there are no retained within the recent evidence window evidence or article summaries to support a current opportunity thesis. Why now: Why now is weak because no articles or evidence were retained after the March 29, 2026 cutoff in these reviewed sources version. Caveats: Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. Membership rationale references article IDs without, which cannot be cited as factual support here. |
| 354 | Portal Space Systems lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources' rationale mentions a $50 million Series A and maneuverable spacecraft technology, but no retained within the recent evidence window article evidence is present here to substantiate a positive thesis. Why now: There is no retained evidence inside the 90-day recent evidence window, so no current catalyst or business-state update is citable from these reviewed sources. Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership rationale references article IDs, and, but no or retained summaries are supplied. Low score reflects lack of citable evidence, not a negative business judgment. |
| 355 | Precursor SPC lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supportable from retained evidence. The phase-2 rationale says Precursor SPC uses Spire data for hypersonic tracking and an AI/ML ionospheric nowcasting system tied to article, but the reviewed sources provide no representative article details, quote, or and no retained evidence after recent evidence window. Why now: Why now is weak because the reviewed sources show no available post-recent evidence window evidence; evidence recent evidence review kept_rows is 0 and coverage data articles after recent evidence window is 0. Caveats: Phase-2 rationale references without or retained evidence detail, so it is not sufficient for factual grounding here. No direct positive or negative evidence arrays are populated. Low scores are an evidence-gap judgment, not a business conclusion. |
| 356 | Quantum Opus lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources references older membership support that Quantum Opus helped build a lunar-Earth laser communication terminal used on Artemis II via article, but there is no retained in-window direct positive evidence with to support a current opportunity thesis. Why now: There is no clear why-now catalyst because coverage after the 90-day recent evidence window is empty. Caveats: Membership support exists but no representative article is provided for. No retained evidence after recent evidence window. No direct business-state update, financing, contract, or customer traction evidence is available. |
| 357 | Quantum Systems GmbH lowweak | Opp 1 Risk 1 | Thesis: No direct positive evidence is available. The reviewed sources say Quantum Systems is mentioned only via founders investing in another startup and as a portfolio-company reference, which is not sufficient for a positive company thesis. Why now: There is no supported near-term or long-horizon catalyst in the reviewed sources because zero post-recent evidence window evidence were available. Caveats: Phase2 rationale references article IDs: and: as article context only, but no were provided in the reviewed sources. Coverage data shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Context-only mentions and portfolio references cannot substitute for direct positive or negative evidence. |
| 358 | Relativity Space lowweak | Opp 1 Risk 2 | Thesis: Relativity Space has a plausible long-horizon opportunity narrative as a rocket developer with financing context in membership rationale, but the reviewed sources contain no retained evidence within the recent evidence window to support a current opportunity call. Why now: Why now is weak because there are no retained post-cutoff article summaries or evidence in the reviewed sources. Caveats: No retained evidence after recent evidence window. The modest risk uplift reflects uncertainty from lack of current confirmation, not a direct adverse event. |
| 359 | Rocket Factory Augsburg lowweak | Opp 1 Risk 2 | Thesis: The membership rationale mentions focus on a first test launch later in the summer, which could be strategically important, but there is no retained evidence row to support a scored positive thesis. Why now: No retained article or event evidence remains after recent evidence filtering; the only hint is a membership rationale referencing first test-launch focus via article: without an included summary. Caveats: Cannot treat membership rationale alone as strong directional proof. No article summary or retained evidence row is included for article |
| 360 | Rogers Communications Inc. lowweak | Opp 1 Risk 1 | Thesis: Only a very weak opportunity read is possible: the reviewed sources rationale says Rogers was mentioned as a Starlink telco partner in a SpaceX IPO article, implying possible exposure to direct-to-device or satellite connectivity, but no in-recent evidence window company evidence or citable article summary were available for Rogers in these reviewed sources. Why now: There is no available 90-day evidence for Rogers in these reviewed sources; coverage data shows zero article ids after recent evidence window and zero evidence after recent evidence window, so there is no supported 'why now' catalyst in the provided evidence. Caveats: No direct positive or negative evidence were available after the 90-day recent evidence window for Rogers. Phase2 rationale references support references including: but no article or article summary for that item is included in these reviewed sources, so it cannot be cited as factual evidence. Opportunity score is kept near zero because the evidence standard require positive evidence, not mere absence of risk. |
Risk view
Showing rows 61-80 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 61 | Xoople mediummedium | Opp 6 Risk 4 | Thesis: Article-level context also highlights structural Earth observation monetization difficulty and long procurement cycles, creating real commercialization risk even after the raise. Why now: Xoople closed a $130 million Series B on April 6, 2026/07 and articles say the capital is for building out its constellation; for a 1 year+ horizon, that financing can enable product and deployment progress, but the same dated coverage warns the market has historically been hard to monetize. Evidence
Caveats: Positive support is mostly supporting article context rather than positive evidence. Commercialization warning is article context, not a company-specific deterioration event. No direct customer, backlog, or launch milestone evidence is available. |
| 62 | AAC Clyde Space AB lowweak | Opp 3 Risk 3 | Thesis: There is no direct adverse evidence in the reviewed sources, so risk is moderate-low and mostly reflects inability to verify current contract progression, funding conversion, or execution status from available evidence (: unavailable in reviewed sources). Why now: Why now is weak because the reviewed sources' recent evidence review and coverage data show zero available evidence after recent evidence window despite the membership rationale referencing a material contract. Caveats: No current evidence is provided for Contract claim appears only in membership rationale, not in available direct evidence fields. No recency-confirmed follow-through evidence is available. |
| 63 | Aavuus mediummedium | Opp 5 Risk 3 | Thesis: Aavuus remains early-stage, and the evidence is supporting article context rather than direct positive events; the same article describes only pre-seed funding, which implies execution and scaling risk over a 1 year+ horizon. Why now: The opportunity is timely because the retained article is dated June 9, 2026 and describes a current financing and product build phase rather than stale background context. That said, recency comes from source date/article date, and evidence grounding is still article-level rather than direct fact/events., June 9, 2026 Evidence
Caveats: Evidence is weak context and supporting article context, not direct structured positive event evidence. No explicit customer, contract, revenue, or regulatory milestone is cited. Same article appears in multiple rows and is not independent confirmation. |
| 64 | Applied Atomics lowweak | Opp 2 Risk 3 | Thesis: Risk is modestly elevated because the reviewed sources' membership rationale describes it as a startup that emerged from stealth and raised only a $4M pre-seed, implying early-stage execution and financing risk, but this is not backed by available dated evidence in the ranking payload. Why now: There is no available dated evidence in the reviewed sources after recent evidence filtering, so recency-based ranking support is weak. Caveats: No representative articles or evidence are available after recent evidence filtering for ranking support. The phase2 membership rationale mentions a $4M pre-seed and Star Reacher Network, but the cited supporting articles are not provided with usable article summaries or evidence in these reviewed sources. |
| 65 | Astrolab lowweak | Opp 3 Risk 3 | Thesis: No direct negative evidence is available; the main risk in this ranking is evidence insufficiency rather than a documented adverse development. Why now: Why-now support is weak because coverage data shows no evidence after recent evidence window, so the cited lunar contract context cannot be refreshed from available evidence. Caveats: Phase2 rationale cites, and: but no representative article or evidence are available for direct citation. Coverage data reports articles after recent evidence window = 0 and evidence after recent evidence window = 0. Private-company watch item rather than high-conviction ranked candidate. |
| 66 | Astroscale lowweak | Opp 5 Risk 3 | Thesis: No direct negative evidence is available. Remaining risk comes from the lack of post-recent evidence window evidence proving contract conversion, revenue realization, or mission execution scale. Why now: Why now is relatively constructive because a named partnership for on-orbit services can matter over a long strategic horizon, but exact timing and materiality cannot be validated from the reviewed sources because only membership rationale is visible. Caveats: Membership rationale references article ID: but the reviewed sources provide no or article summary. Relation counts are present in support metadata, but relations are context-only unless separately policy-gated. No direct positive or negative evidence arrays are populated. |
| 67 | Axelspace Corporation lowweak | Opp 3 Risk 3 | Thesis: No material negative evidence is present; risk is mainly execution and evidence-gap risk because current launch timing, deployment success, and monetization are not substantiated by the available reviewed sources evidence (: unavailable in reviewed sources). Why now: Why now is weak because the reviewed sources references a potentially important constellation expansion but provides no post-recent evidence window available evidence to confirm status or timing. Caveats: No current evidence is provided for No direct evidence remained after the recent evidence filter. Recency of constellation expansion cannot be validated from reviewed sources fields. |
| 68 | CAS Space lowweak | Opp 2 Risk 3 | Thesis: Risk is modestly elevated because the membership rationale describes IPO and reusable rocket development ambitions, both of which imply capital intensity and execution risk, but there is no available adverse evidence. Why now: There is no usable dated evidence available after recent evidence filtering, so the reviewed sources does not provide a clear timing catalyst. Caveats: The membership rationale references an IPO and Lijian-1 launch activity, but those source articles are not included with ranking-usable details in these reviewed sources. |
| 69 | CesiumAstro lowweak | Opp 5 Risk 3 | Thesis: The positive financing evidence is stale relative to the reviewed sources' 90-day recent evidence window. The article is dated February 14, 2026, which the reviewed sources say was dropped by the recent evidence filter, so there is no current-window evidence confirming whether financing momentum, backlog conversion, or product adoption continued Why now: There is no fresh catalyst inside the 90-day evidence window. The visible article was published on February 14, 2026 and is outside the cutoff date of March 29, 2026, so it is useful as background but weak for recency-sensitive ranking Evidence
Caveats: The visible positive article is outside the 90-day recent evidence window cutoff and was dropped from reviewed evidence. External supporting source context is allowed as evidence context but is not merged into primary data source. |
| 70 | ClearSpace mediummedium | Opp 7 Risk 3 | Thesis: Risks center on execution and evidence quality rather than explicit adverse news. The financing article carries internal chronology ambiguity because the page was published in 2026 but references a January 19, 2023 financing round, and the overall reviewed sources lack direct negative events, contract-performance data, or milestone completion proof. Why now: Why now is supported by recent dated context: on June 24, 2026, SpaceNews reported ClearSpace signed an MOU with Shield Space to develop sovereign space defense capabilities for the UK and allies, indicating adjacent market expansion. On May 19, 2026, the company site said it had finalized a EUR 26.7 million Series A and was ramping operations ahead of ClearSpace-1 scheduled to launch in 2026. These dated items fit a 1 year+ horizon because they point to ongoing commercialization and mission preparation. Evidence
Caveats: Most evidence is supporting article context, not direct positive events. The financing article published on May 19, 2026 references January 19, 2023 for the Series A round, so funding recency versus page recency should not be conflated. |
| 71 | D-Orbit lowweak | Opp 4 Risk 3 | Thesis: No direct negative evidence is present. Risk remains moderate because the evidence base is only one cited article with no available direct events, leaving uncertainty on commercialization, timeline, and conversion from demonstration activity to durable revenue. Why now: Why now is the partnership/demo claim referenced in article ID, but the reviewed sources includes neither nor explicit article timing beyond the article ID prefix, limiting recency precision. Caveats: Opportunity rests on membership rationale rather than fully available direct evidence. Referenced article ID has no in the reviewed sources. Demo activity is not the same as proven commercial traction. |
| 72 | Dawn Aerospace mediummedium | Opp 7 Risk 3 | Thesis: Risk is non-trivial because the thesis depends on execution of a global rollout in a capital-intensive reusable space transportation market, but the reviewed sources does not show direct adverse events. Risk is therefore moderate rather than high. Why now: The key catalyst is recent and explicit: on June 16, 2026 the company announced the Series B close and said the proceeds will finance global rollout and scaling of commercial and operational teams in the US and Europe. Evidence
Caveats: Evidence comes from a company-published article, so it is not fully independent. No direct structured positive event row is provided beyond supporting article context. |
| 73 | Earth Eye Co lowweak | Opp 2 Risk 3 | Thesis: Because the reviewed sources frames the company around surveillance/spy satellite activity rather than commercial traction, and provides no direct positive operating evidence, the name screens as a limited-visibility watchlist with modest evidence-based risk. Why now: Why now is weak because there are no available post-recent evidence window evidence, no article summaries, and no clear near- or long-horizon catalyst beyond generic association with a surveillance satellite. Caveats: Membership rationale cites article IDs and, but the reviewed sources provide no. Company is private and evidence coverage inside the recent evidence window is empty. |
| 74 | EDGX lowweak | Opp 4 Risk 3 | Thesis: Execution and financing risk remain material because the reviewed sources contain no kept direct evidence on follow-on funding, customer adoption, revenue conversion, or post-demo performance; technology demonstration does not by itself prove scale-up. Why now: The membership support references articles, and, implying a narrative of funding plus orbital demonstration, but active evidence remains empty after recent evidence filtering, limiting recency confidence. Caveats: In-orbit demo claim appears only in reviewed sources rationale, not available direct evidence. No evidence confirms whether the prior seed round falls within the current decision horizon relevance. No direct adverse evidence is present, but that is not proof of low fundamental risk. |
| 75 | Ellipsis Drive lowweak | Opp 4 Risk 3 | Thesis: Risk is mostly commercialization uncertainty. The reviewed sources does not provide direct negative evidence, but it also lacks direct available proof of revenue, customer conversion, or broader market adoption. Why now: Why now is the reviewed sources' claim that the company addresses a key EO data-processing bottleneck and has space-agency support, referenced to article ID: though no or timestamp detail was provided. Caveats: Claims come from membership rationale rather than direct evidence. Referenced article ID: lacks a reviewed sources. Support from agencies and target users is weaker than demonstrated contracted revenue. |
| 76 | EON Space Labs lowweak | Opp 1 Risk 3 | Thesis: The reviewed sources' clearest adverse context is that EON Space Labs was identified as one of the Indian private space companies affected by a PSLV failure, which could create execution, schedule, or financing ripple effects over a 1 year+ horizon, though the underlying article detail is not surfaced in the scoring evidence fields. Why now: Why now is stronger than for most names here because the phase2 rationale specifically ties EON Space Labs to a PSLV failure context via article: implying a concrete event rather than generic company context. However, conviction remains low because the reviewed sources omits the underlying event summary and dates in the evidence exposed here. Caveats: The adverse signal appears only in phase2 rationale, not in direct negative evidence. No article summary, quote, or timing detail is provided in the scoring fields. Impact magnitude on EON specifically cannot be quantified from these reviewed sources alone. |
| 77 | Eycore mediumweak | Opp 5 Risk 3 | Thesis: Risk remains moderate because the reviewed sources offers only one supporting article context and no direct positive event row beyond that summary, leaving unclear whether the satellite is generating revenue, delivering performance, or leading to follow-on orders. Why now: Why now is the dated first-satellite launch article from May 5, 2026, which is recent within the 90-day recent evidence window and relevant to a long-horizon de-risking story, though still early-stage. Evidence
Caveats: Evidence is supporting article context only, not a stronger structured positive event row. Single-article universe limits corroboration. No financing, customer, revenue, or performance follow-through evidence is provided. |
| 78 | GITAI mediummedium | Opp 6 Risk 3 | Thesis: Execution and commercialization risk remain meaningful because the retained evidence is still mainly company-provided article context and a technology demonstration milestone, not third-party validated contract wins, revenue conversion, or mission success; an undated directory listing that GITAI is 'operating' is weaker context and not recency proof. Why now: The key catalyst is recent and inside recent evidence window: on June 16, 2026, GITAI announced completion of the S3 flight model for an on-orbit servicing demonstration mission, which is directly relevant to a 1 year+ horizon because it may precede launch, demonstration, and downstream defense/commercial adoption over the next year. Evidence
Caveats: Primary evidence is from the company itself. No retained independent customer, contract, or revenue evidence is provided. The spaceindex.io entry is undated and should not be treated as recency proof. |
| 79 | Goonhilly Earth Station Ltd lowweak | Opp 3 Risk 3 | Thesis: The same reviewed sources rationale says Goonhilly is being acquired by Intuitive Machines, which can create integration, ownership, and business-state uncertainty over a 1 year+ horizon. Because no retained dated evidence are available, this risk is only moderately ranked. Why now: The only 'why now' available is the reviewed sources' statement that Goonhilly is being acquired by Intuitive Machines, cited in phase-2 support, and: but no, timestamps, or retained evidence are provided, so recency and sequence cannot be validated. Caveats: The reviewed sources rationale states Goonhilly has ground-station/COMSAT revenue and is being acquired by Intuitive Machines, tied to, and: but no or retained evidence are present. Coverage debug still shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Because chronology cannot be verified, transaction-state claims should be treated cautiously. |
| 80 | ICEYE highstrong | Opp 9 Risk 3 | Thesis: The reviewed sources does not show material adverse company-specific events; main risk is that most support is financing/context evidence rather than audited operating metrics or margins. Why now: On June 9, 2026 ICEYE disclosed a €450 million primary Series F at valuation above €10 billion, with total round size above €1 billion including secondary, and later June context also referenced a €300 million revolving credit facility and additional sovereign satellite demand; those are recent business-state signals for a 1 year+ horizon. Evidence
Caveats: Some support is supporting article context rather than company-specific positive evidence. Several supporting demand/customer references are undated, so recency is uncertain for those claims. |